Manolis Kellis: Biology of Disease

The episode begins with Lex framing the challenge of understanding human disease through the lens of genetic complexity, as Manolis Kellis describes the vast number of genetic perturbations each person carries. Kellis emphasizes that the complexity of human disease is akin to that of the human genome and immune system, with 6 million unique genetic variants per person acting as potential health perturbations. He argues that genetic epidemiology can help establish causality by correlating genetic changes with phenotypic differences, moving beyond traditional family pedigree studies to large cohort analyses.

Kellis then delves into the revolutionary impact of CRISPR technology on genome editing, highlighting its simplicity in guiding RNA sequences to target specific DNA regions. Unlike older methods requiring complex protein engineering, CRISPR allows for straightforward design of RNA guides, streamlining the editing process. Kellis explains that this ease of use accelerates research and therapeutic development, as it enables precise genome edits without the need for extensive protein manipulation. Prime editing, a newer CRISPR technique, offers even more precision by making single-stranded DNA breaks.

Despite the transformative potential of CRISPR, Kellis faces no direct pushback from Lex, who seems to accept the guest's assertions about its revolutionary nature. However, a point of tension arises when discussing the FTO gene's role in obesity. Kellis reveals that previous assumptions about FTO were incorrect; it actually regulates distant genes IRX3 and IRX5, which are crucial for lipid metabolism and thermogenesis. This revelation challenges the conventional understanding of genetic regulation, highlighting the need to consider non-coding regions and distant gene interactions.

The conversation shifts to Alzheimer's disease, where Kellis presents surprising findings about the role of microglia in disease progression. Contrary to the neuron-centric view, genetic studies show that microglia, the brain's immune cells, are significantly enriched in Alzheimer's samples. This suggests a shift in focus for potential treatments, emphasizing the interconnectedness of genetic pathways across various diseases. The episode concludes with Kellis advocating for a holistic approach to disease research, integrating genetic, metabolic, and environmental factors to develop more effective interventions.